Prescient Healthcare Group, a science and insight-led development and commercialization partner for the pharmaceutical and biotechnology industries, has acquired Dolon, a London-based consultancy specializing in strategic pricing and market access. The transaction strengthens Prescient’s ability to support global biopharma companies navigating increasingly complex clinical, commercial, and access environments.
The acquisition follows Prescient’s earlier purchase of Uptake Strategies this year and represents another step in its broader growth strategy. Dolon will continue operating with its specialist focus as a dedicated Value, Pricing, and Access practice within Prescient, working alongside existing teams to deliver integrated support across the product lifecycle.
By combining capabilities, the companies aim to provide earlier and more comprehensive strategic insights for clients, particularly in pricing, reimbursement, and market access decisions that are critical to bringing innovative medicines to patients. The deal also expands Prescient’s global platform, enhances its U.S. presence, and strengthens its analytical and AI-driven capabilities.
The transaction was supported by Bridgepoint, which has backed Prescient since 2021 through its Bridgepoint Development Capital fund. Financial terms of the acquisition were not disclosed.
Dolon, headquartered in London with teams across the United States and Europe, specializes in rare diseases and oncology. Its expertise in value strategy, pricing, and access policy, combined with advanced analytics, complements Prescient’s broader scientific and commercial advisory capabilities.
KEY QUOTES:
“Dolon brings deep strategic pricing and market access expertise and a strong cultural alignment that makes this a natural fit for Prescient. As the environment for pricing and reimbursement continues to evolve, strengthening our capabilities in this area enhances our ability to provide expanded lifecycle support to clients where and when they need it. This acquisition reflects our commitment to purposeful growth and to building the specialist expertise that supports the success of our clients.”
Jason McKenna, CEO, Prescient Healthcare Group
“Prescient stood out for its strategic thinking, long-term partnerships with senior global decision makers and strong cultural alignment. Joining Prescient gives us the platform to scale our impact, combining our specialist expertise with broader clinical, commercial and RWE solutions, a stronger US presence and enhanced AI capabilities. Together, we can support clients earlier and more comprehensively across the product lifecycle, helping accelerate access to innovative medicines for patients. We’re excited about what this enables for our clients and our team.”
Adam Hutchings, Managing Partner, Dolon
“Dolon represents a strong strategic addition to Prescient, complementing existing skills and adding value, pricing and market access capabilities. The acquisition further strengthens Prescient’s offer to clients and demonstrates continued momentum in the growth strategy prosecuted over the past five years with Bridgepoint’s support.”
Alan Payne, Partner And Deputy Head Of Bridgepoint Development Capital, Bridgepoint
